Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement

NEW PUBLICATION: EMAS is extremely proud to announce the EMAS 2021 Global Recommendations on Menopause in the Workplace. This will be followed by a Menopause Charter for employers and a Self-Assessment tool for employers and managers. Read more: https://www.emas-online.org/emas-and-menopause-in-the-workplace-2021 Menopause in the Workplace

Details

Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide

Vulvovaginal atrophy is a chronic condition caused by estrogen deficiency which affects around 50% of postmenopausal women.  EMAS has published a clinical guide on the use of both topical estrogens and non-hormonal lubricants and moisturizers so that treatment can be individualized. Read more https://www.sciencedirect.com/science/article/pii/S037851222100061X

Details

EMAS and IGCS Position statement on managing the menopause after gynecological cancer

February 11, 2020 – European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) Position statement on managing the menopause after gynecological cancer Worldwide, 1.3 million new gynecological cancer cases are diagnosed each year. Treatment can result in loss of ovarian function and, in women under the age of 45, early menopause.  This position…

Details

Management of urinary incontinence in postmenopausal women: an EMAS clinical guide Maturitas 2021; 143: 223–230

30 September 2020 – A new clinical guide by the European Menopause and Andropause Society (EMAS) on the management of urinary incontinence in postmenopausal women is published in Maturitas. Urinary incontinence affects over 1 in 2 women aged over 60 years. The clinical guide provides evidence-based recommendations for the diagnosis and management of this common…

Details